The Effect of Antifibrotic Drug Halofugine on Th17 Cells in Concanavalin A-Induced Liver Fibrosis

Scandinavian Journal of Immunology

Volumn 79, Issue 3, 2014, Pages 163-172

  Liang, J ^a   Zhang, B ^a   Shen, R W ^a   Liu, J B ^b   Gao, M H ^a   Geng, X ^a   Li, Y ^a   Li, Y Y ^a   Zhang, W ^a  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^b QINGDAO UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN; CONCANAVALIN A; EOSIN; GAMMA INTERFERON; HALOFUGINONE; HEMATOXYLIN; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 33; INTERLEUKIN 6; RETINOID RELATED ORPHAN RECEPTOR GAMMA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFIBROTIC ACTIVITY; ARTICLE; BIOACCUMULATION; CONCANAVALIN A INDUCED LIVER FIBROSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG ACTIVITY; EXPERIMENTAL LIVER FIBROSIS; FLOW CYTOMETRY; HISTOPATHOLOGY; IN VIVO STUDY; LIVER; LYMPHOCYTE; LYMPHOCYTE COUNT; MALE; MASSON STAINING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT MODEL; SPLEEN CELL; STAINING; TH17 CELL;

ACTINS; ALANINE TRANSAMINASE; ALBUMINS; ANIMALS; ASPARTATE AMINOTRANSFERASES; CELL DIFFERENTIATION; CONCANAVALIN A; DISEASE MODELS, ANIMAL; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-17; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTERLEUKINS; LIVER; LIVER CIRRHOSIS; MALE; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP F, MEMBER 3; PIPERIDINES; PROTEIN SYNTHESIS INHIBITORS; QUINAZOLINONES; RATS; RATS, WISTAR; TH17 CELLS; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84894473108     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12144     Document Type: Article

References (58)

1. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008;134:1655-69.
2. Barron L, Wynn TA. Interactions between fibroblasts, macrophages, Th2 and Th17 immunity regulate fibrosis. Am J Physiol-Gastrointest Liver Physiol 2011;300:G723-8.
3. Zhang D-W, Zhao Y-X, Wei D et al. HAb18G/CD147 promotes activation of hepatic stellate cells and is a target for antibody therapy of liver fibrosis. J Hepatol 2012;57:1283-91.
4. Kisseleva T, Brenner DA. Role of hepatic stellate cells in fibrogenesis and the reversal of fibrosis. J Gastroenterol Hepatol 2007;22:S73-8.
5. Bataller R, Brenner DA. Liver fibrosis. J Clin Inves 2005;115:209-18.
6. Lotersztajn S, Julien B, Teixeira-Clerc F, Grenard P, Mallat A. Hepatic fibrosis: molecular mechanisms and drug targets. Annu Rev Pharmacol Toxicol 2005;45:605-28.
7. Voo KS, Wang Y-H, Santori FR et al. Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci 2009;106:4793-8.
8. Tang Y, Bian Z, Zhao L et al. Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease. Clin Exp Immunol 2011;166:281-90.
9. Hammerich L, Heymann F, Tacke F. Role of IL-17 and Th17 cells in liver diseases. Clin Dev Immunol 2010;2011:345803.
10. Zhang JY, Zhang Z, Lin F et al. Interleukin-17-producing CD4+ T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology 2010;51:81-91.
11. Gao B, Waisman A. Th17 cells regulate liver fibrosis by targeting multiple cell types: many birds with one stone. Gastroenterology 2012;143:536-9.
12. Zhang J-Y, Zou Z-S, Huang A et al. Hyper-activated pro-inflammatory CD16+ monocytes correlate with the severity of liver injury and fibrosis in patients with chronic hepatitis B. PLoS ONE 2011;6:e17484.
13. Lemmers A, Moreno C, Gustot T et al. The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology 2009;49:646-57.
14. Yao Z, Painter SL, Fanslow WC et al. Human IL-17: a novel cytokine derived from T cells. J Immunol 1995;155:5483-6.
15. Rouvier E, Luciani M, Mattei M, Denizot F, Golstein P. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol 1993;150:5445-56.
16. Park H, Li Z, Yang XO et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005;6:1133-41.
17. Lafdil F, Miller AM, Ki SH, Gao B. Th17 cells and their associated cytokines in liver diseases. Cell Mol Immunol 2010;7:250-4.
18. Abramovitch R, Dafni H, Neeman M, Nagler A, Pines M. Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis. Neoplasia (New York, NY) 1999;1:321.
19. Karatas A, Paksoy M, Erzin Y et al. The effect of halofuginone, a specific inhibitor of collagen type 1 synthesis, in the prevention of pancreatic fibrosis in an experimental model of severe hyperstimulation and obstruction pancreatitis. J Surg Res 2008;148:7.
20. Bruck R, Genina O, Aeed H et al. Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Hepatology 2001;33:379-86.
21. Benchetrit S, Yarkoni S, Rathaus M et al. Halofuginone reduces the occurrence of renal fibrosis in 5/6 nephrectomized rats. Isr Med Assoc J 2007;9:30.
22. Pines M, Snyder D, Yarkoni S, Nagler A. Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Biol Blood Marrow Transplant 2003;9:417-25.
23. Jaidane M, Ali-El-Dein B, Ounaies A, Hafez AT, Mohsen T, Bazeed M. The use of halofuginone in limiting urethral stricture formation and recurrence: an experimental study in rabbits. J Urol 2003;170:2049-52.
24. Arbell D, Udassin R, Koplewitz BZ et al. Prevention of esophageal strictures in a caustic burn model using halofuginone, an inhibitor of collagen type I synthesis. Laryngoscope 2005;115:1632-5.
25. Nelson EF, Huang CW, Ewel JM, Chang AA, Yuan C. Halofuginone down-regulates Smad3 expression and inhibits the TGFbeta-induced expression of fibrotic markers in human corneal fibroblasts. Mol Vis 2012;18:479.
26. Gupta SC, Sundaram C, Reuter S, Aggarwal BB. Inhibiting NF-κB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta 2010;1799:775-87.
27. Tiegs G, Hentschel J, Wendel A. AT cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin invest 1992;90:196.
28. Itoh A, Isoda K, Kondoh M et al. Hepatoprotective effect of syringic acid and vanillic acid on concanavalin a-induced liver injury. Biol Pharm Bull 2009;32:1215-9.
29. Zhou J, Ju W, Wang D et al. Down-regulation of microRNA-26a promotes mouse hepatocyte proliferation during liver regeneration. PLoS ONE 2012;7:e33577.
30. Chevallier M, Guerret S, Chossegros P, Gerard F, Grimaud JA. A histological semiquantitative scoring system for evaluation of hepatic fibrosis in needle liver biopsy specimens: comparison with morphometric studies. Hepatology 1994;20:349-55.
31. Lee CK, Perez-Atayde AR, Mitchell PD, Raza R, Afdhal NH, Jonas MM. Serum biomarkers and transient elastography as predictors of advanced liver fibrosis in a United States cohort: the Boston children's hospital experience. J Pediatr 2013;163:1058-64.
32. Thannickal VJ, Lee DY, White ES et al. Myofibroblast differentiation by transforming growth factor-β1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J Biol Chem 2003;278:12384-9.
33. Gonzalez GE, Rhaleb N-E, Nakagawa P et al. N-acetyl-seryl-aspartyl-lysyl-proline reduces cardiac collagen cross-linking and inflammation in angiotensin II-induced hypertensive rats. Clin Sci 2014;126:85-94.
34. +T helper cells. Cell 2006;126:1121-33.
35. McClain C, Hill D, Schmidt J, Diehl AM. Cytokines and alcoholic liver disease. Semin Liver Dis 1993;13:170-82.
36. Weng H, Mertens PR, Gressner AM, Dooley S. IFN-γ abrogates profibrogenic TGF-β signaling in liver by targeting expression of inhibitory and receptor Smads. J Hepatol 2007;46:295-303.
37. 1 density in the post-MI heart. J Mol Cell Cardiol 2005;38:505-15.
38. Shahar I, Fireman E, Topilsky M et al. Effect of IL-6 on alveolar fibroblast proliferation in interstitial lung diseases. Clin Immunol Immunopathol 1996;79:244-51.
39. Mchedlidze T, Waldner M, Zopf S et al. Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis. Immunity 2013;39:357-71.
40. McGeachy MJ, Bak-Jensen KS, Chen Y et al. TGF-β and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain TH-17 cell-mediated pathology. Nat Immunol 2007;8:1390-7.
41. de Figueiredo-Pontes LL, Assis PA, Santana-Lemos BA et al. Halofuginone has anti-proliferative effects in acute promyelocytic leukemia by modulating the transforming growth factor beta signaling pathway. PLoS ONE 2011;6:e26713.
42. Leiba M, Cahalon L, Shimoni A et al. Halofuginone inhibits NF-κB and p38 MAPK in activated T cells. J Leukoc Biol 2006;80:399-406.
43. Elkin M, Miao H-Q, Nagler A et al. Halofuginone: a potent inhibitor of critical steps in angiogenesis progression. Faseb J 2000;14:2477-85.
44. Spira G, Mawasi N, Paizi M et al. Halofuginone, a collagen type I inhibitor improves liver regeneration in cirrhotic rats. J Hepatol 2002;37:331-9.
45. Sundrud MS, Koralov SB, Feuerer M et al. Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response. Science 2009;324:1334-8.
46. Watanabe A, Kobayashi M, Hayashi S et al. Protection against D-galactosamine-induced acute liver injury by oral administration of extracts from Lentinus edodes mycelia. Biol Pharm Bull 2006;29:1651-4.
47. Zhao L, Qiu DK, Ma X. Th17 cells: the emerging reciprocal partner of regulatory T cells in the liver. J Dig Dis 2010;11:126-33.
48. Kolls JK, Lindén A. Interleukin-17 family members and inflammation. Immunity 2004;21:467-76.
49. Wang L, Chen S, Xu K. IL-17 expression is correlated with hepatitis B-related liver diseases and fibrosis. Int J Mol Med 2011;27:385-92.
50. Li J, Qiu S-J, She W-M et al. Significance of the balance between regulatory T (Treg) and T helper 17 (Th17) cells during hepatitis B virus related liver fibrosis. PLoS ONE 2012;7:e39307.
51. Bengsch B, Seigel B, Flecken T, Wolanski J, Blum HE, Thimme R. Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26). J Immunol 2012;188:5438-47.
52. Eberl G, Littman DR. The role of the nuclear hormone receptor RORγt in the development of lymph nodes and Peyer's patches. Immunol Rev 2003;195:81-90.
53. Villey I, de Chasseval R, de Villartay JP. RORγT, a thymus-specific isoform of the orphan nuclear receptor RORγ/TOR, is up-regulated by signaling through the pre-T cell receptor and binds to the TEA promoter. Eur J Immunol 1999;29:4072-80.
54. Ivanov II, Zhou L, Littman DR. Transcriptional regulation of Th17 cell differentiation. Semin Immunol 2007;19:409-17.
55. Batra V, Musani A, Hastie A et al. Bronchoalveolar lavage fluid concentrations of transforming growth factor (TGF)-β1, TGF-β2, interleukin (IL)-4 and IL-13 after segmental allergen challenge and their effects on α-smooth muscle actin and collagen III synthesis by primary human lung fibroblasts. Clin Exp Allergy 2004;34:437-44.
56. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006;24:179-89.
57. Xiao S, Jin H, Korn T et al. Retinoic acid increases Foxp3+ regulatory T cells and inhibits development of Th17 cells by enhancing TGF-β-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression. J Immunol 2008;181:2277-84.
58. Albanis E, Friedman SL. Hepatic fibrosis: pathogenesis and principles of therapy. Clin Liver Dis 2001;5:315-34.